Symbiotec Pharmalab Limited (SYMBIOTEC) fundamentals
Symbiotec Pharmalab Limited is a listed company, part of the Pharmaceuticals sector, listed on the NSE as SYMBIOTEC (ISIN INE899I01028). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
Valuation and market data
| Last close | ₹1133.45 |
|---|---|
| Market capitalisation | ₹6,522 crore |
| Enterprise value | ₹6,615 crore |
| P/E (TTM) | 5.69 |
| Price to book | 5.67 |
| Price to sales (TTM) | 2.56 |
| Book value per share | ₹199.79 |
| Dividend yield | 0.00% |
| Sector | Pharmaceuticals |
| Industry | — |
| Listed since | Tue Sep 01 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹872 crore | ₹153 crore | ₹110 crore | 19.10 |
| Mar 2025 | ₹756 crore | ₹147 crore | ₹97 crore | 88.50 |
| Mar 2024 | ₹723 crore | ₹132 crore | ₹101 crore | 91.49 |
| Mar 2023 | ₹573 crore | ₹39 crore | ₹25 crore | 21.48 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Aug 2026:
| Promoters | 33.3% |
|---|---|
| Foreign institutions (FII) | 21.1% |
| Mutual funds | 5.5% |
| Other domestic institutions | 22.0% |
| Retail and others | 18.1% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.